ASRGL1

Across TCGA pan-cancer cohorts, ASRGL1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ASRGL1 data layer compared with 22 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ASRGL1 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ASRGL1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, OV, and LUAD are the cancer types where ASRGL1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	II,III,IV	0.963	0.703	.003	26	view →
OV	DFS	Median	All	0.862	1.000	.031	4	view →
LUAD	DFS	Quartile	III,IV	0.481	1.000	.040	4	view →
CCRCC	OS	Tertile	All	1.000	0.657	.030	3	view →
HNSC	OS	Quartile	II,III,IV	0.932	1.000	.033	1	view →
LSCC	DFS	Tertile	All	0.888	0.989	.012	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ASRGL1–PDAC (OS)

Open the PDAC breakdown →